Renal cancer. Issue 10 (October 2022)

• Record Type: Journal Article
• Authors: Janebdar, Husay; Fernandes, Megan; Manson-Bahr, David
• Is Part Of: Surgery. Volume 40:Issue 10(2022)
• Page Start: 653
• Page End: 659
• Publication Date: 2022-10
• Subjects: Partial nephrectomy -- renal cancer -- renal cell carcinoma -- radical nephrectomy; Surgery -- Periodicals; Surgery -- Periodicals; Chirurgie -- Périodiques; Thérapeutique -- Périodiques; Electronic journals; 617
• DOI: 10.1016/j.mpsur.2022.08.001
• Languages: English
• ISSNs: 0263-9319

Abstract

Abstract: Renal cell carcinoma (RCC) is an adenocarcinoma of the renal cortex. It is the commonest type of kidney cancer and accounts for over 85% of renal cancer diagnoses. The remaining malignancies are transitional cell carcinomas, sarcomas, Wilms' tumour, and rarely lymphomas and metastatic deposits. 10%–15% of renal masses are benign, such as oncocytomas and angiomyolipomas. Simple renal cysts are benign, however more complex renal cysts have a risk of being malignant. Renal cell carcinoma is commonly diagnosed at an earlier stage due to the widespread availability of imaging, and as a result the described classic triad of symptoms of haematuria, renal angle pain and a palpable mass is increasingly uncommon. The management of renal cancer includes active surveillance for older, comorbid patients, nephron-sparing surgery or ablative therapies for smaller renal masses, radical nephrectomy for larger tumours, and systemic treatment with a combination of immunotherapies and tyrosine kinase inhibitors and for metastatic disease.